GFAP and Alzheimer disease: Studies from a triple transgenic mouse model of AD, which mimics the progression of the disease in humans, show that the patterns of GFAP expression differ among brain areas and during the different phases of the neurodegenerative process (Olabarria et al., 2010; Yeh et al., 2011).